TG Therapeutics Inc (TGTX) is -10.91% away from 50-day simple Moving Average despite all headwinds

On Monday, TG Therapeutics Inc (NASDAQ: TGTX) opened lower -4.19% from the last session, before settling in for the closing price of $28.88. Price fluctuations for TGTX have ranged from $12.84 to $36.84 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has jumped its sales by 3133.08% annually for the last half of the decade. Company’s average yearly earnings per share was noted 14.81% at the time writing. With a float of $140.52 million, this company’s outstanding shares have now reached $155.78 million.

In an organization with 264 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 88.22%, operating margin of -0.19%, and the pretax margin is -5.24%.

TG Therapeutics Inc (TGTX) Insider and Institutional Ownership

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of TG Therapeutics Inc is 9.73%, while institutional ownership is 65.85%. The most recent insider transaction that took place on Jan 03 ’25, was worth 343,443. In this transaction CFO of this company sold 11,337 shares at a rate of $30.29, taking the stock ownership to the 670,632 shares. Before that another transaction happened on Jan 06 ’25, when Company’s CFO sold 10,021 for $28.53, making the entire transaction worth $285,939. This insider now owns 660,611 shares in total.

TG Therapeutics Inc (TGTX) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.14 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 14.81% per share during the next fiscal year.

TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators

Check out the current performance indicators for TG Therapeutics Inc (TGTX). In the past quarter, the stock posted a quick ratio of 3.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.27.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.11, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 1.00 in one year’s time.

Technical Analysis of TG Therapeutics Inc (TGTX)

Let’s dig in a bit further. During the last 5-days, its volume was 3.29 million. That was better than the volume of 2.99 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 17.14%. Additionally, its Average True Range was 1.70.

During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 41.70%, which indicates a significant increase from 6.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.31% in the past 14 days, which was lower than the 61.39% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $31.06, while its 200-day Moving Average is $22.36. However, in the short run, TG Therapeutics Inc’s stock first resistance to watch stands at $28.34. Second resistance stands at $29.01. The third major resistance level sits at $29.56. If the price goes on to break the first support level at $27.12, it is likely to go to the next support level at $26.57. The third support level lies at $25.90 if the price breaches the second support level.

TG Therapeutics Inc (NASDAQ: TGTX) Key Stats

There are currently 155,665K shares outstanding in the company with a market cap of 4.31 billion. Presently, the company’s annual sales total 233,660 K according to its annual income of 12,670 K. Last quarter, the company’s sales amounted to 83,880 K and its income totaled 3,880 K.